Cargando…
Targets for future clinical trials in Huntington's disease: What's in the pipeline?
The known genetic cause of Huntington's disease (HD) has fueled considerable progress in understanding its pathobiology and the development of therapeutic approaches aimed at correcting specific changes linked to the causative mutation. Among the most promising is reducing expression of mutant...
Autores principales: | Wild, Edward J, Tabrizi, Sarah J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265300/ https://www.ncbi.nlm.nih.gov/pubmed/25155142 http://dx.doi.org/10.1002/mds.26007 |
Ejemplares similares
-
Huntington’s Disease Clinical Trials Corner: August 2023
por: Estevez-Fraga, Carlos, et al.
Publicado: (2023) -
Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel
por: Psotka, Mitchell A., et al.
Publicado: (2020) -
Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week
por: Fanaroff, Alexander C., et al.
Publicado: (2020) -
The Consequences of the COVID-19 Pandemic on Non-COVID-19 Clinical Trials
por: Bagiella, Emilia, et al.
Publicado: (2020) -
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
por: Talasaz, Azita H., et al.
Publicado: (2021)